FindTrial
Sign In

Matching vehicle control

DRUG3 trials

Sponsors

Pfizer, Eupraxia Pharmaceuticals Inc.

Conditions

Dermatitis, AtopicEosinophilic Esophagitis

Phase 1

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
RecruitingNCT05608681
Eupraxia Pharmaceuticals Inc.Eosinophilic Esophagitis
Start: 2023-03-31End: 2026-12-01Target: 117Updated: 2026-03-19

Phase 3

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
CompletedNCT02118766
PfizerDermatitis, Atopic
Start: 2014-03-31End: 2015-04-30Updated: 2017-03-06
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
CompletedNCT02118792
PfizerDermatitis, Atopic
Start: 2014-03-31End: 2015-04-30Updated: 2017-03-06

Related Papers

265. INITIAL RESULTS FROM RESOLVE, A PHASE 1B DOSE-ESCALATION STUDY OF EP-104GI (EXTENDED-RELEASE FLUTICASONE PROPIONATE INTRA-ESOPHAGEAL INJECTION) FOR EOSINOPHILIC ESOPHAGITIS
Diseases of the Esophagus2024-09-01
Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis
Dermatitis2024-01-115 citations
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
American Journal of Clinical Dermatology2023-05-1533 citations
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
2023-02-223 citations
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
2022-03-1613 citations
Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities
Allergy and Asthma Proceedings2021-09-0111 citations
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Dermatology and Therapy2021-08-1111 citations
Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
2021-03-131 citations
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
Pediatric Dermatology2020-09-2711 citations
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
2020-04-0155 citations
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
Acta Dermato Venereologica2020-01-0113 citations
Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
2019-07-0712 citations
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis
Acta Dermato Venereologica2019-01-0111 citations
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
2018-10-2218 citations
Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS)
Itch2018-06-0114 citations
Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials
Itch2018-06-019 citations
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
2016-07-11356 citations